In a report released today, Oliver McCammon from LifeSci Capital maintained a Buy rating on Janux Therapeutics Inc (JANX – Research Report), with a price target of $100.00.
Oliver McCammon has given his Buy rating due to a combination of factors that highlight the potential of Janux Therapeutics Inc’s pipeline. The updated results from the Phase 1a trial of their PSMA x CD3 T cell engager, JANX007, show promising median radiographic progression-free survival (rPFS) of 7.5 months in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients. This is significant given the advanced stage of treatment these patients have undergone, indicating the potential efficacy of JANX007 in challenging clinical settings.
Furthermore, the initiation of Phase 1b expansion studies suggests confidence in the continued development and potential success of this therapeutic asset. The comparison with Pluvicto’s performance in earlier trials, which showed improved progression-free survival in less heavily treated populations, supports the possibility that JANX007 could demonstrate even more favorable outcomes in earlier treatment lines. These factors collectively suggest a positive outlook for Janux’s therapeutic candidates, justifying the Buy rating.
According to TipRanks, McCammon is an analyst with an average return of -12.6% and a 25.00% success rate. McCammon covers the Healthcare sector, focusing on stocks such as Monte Rosa Therapeutics, Janux Therapeutics Inc, and Aura Biosciences Inc.